ClinicalTrials.gg
CompletedNCT01622231Updated Jan 9, 2017Results posted

Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

A Phase 3 interventional study of Fluticasone furoate in Rhinitis, sponsored by GlaxoSmithKline. Completed at 6 sites in Japan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Rhinitis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis · GlaxoSmithKline.

Enrollment
9th of 21
61 · median 56
Started
2012
with 3 others
Phase 3
4 of 25
none open now
Registered
16th of 25
by date

Among the 25 studies in Rhinitis by GlaxoSmithKline, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 3, and was the 16th registered.

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

Browse Rhinitis studies →

Open to participants now

None of the 25 studies in Rhinitis by GlaxoSmithKline is open now. The open studies under Rhinitis, anywhere →

Who these studies take

Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Rhinitis by GlaxoSmithKline as a file.
02

Study summary

Safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will be evaluated. And secondarily, efficacy and systemic exposure of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will also be evaluated.

03

Conditions studied

  • Rhinitis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2 to \<15 years of age, male or eligible female (females of must commit to consistent and correct use of an acceptable method of ), outpatient
  • Diagnosis of perennial allergic rhinitis: A positive test response to house dust and/or dust mites on serum antigen-specific IgE antibody test at Visit 1. Six months or more clinical history of perennial allergic rhinitis. A positive test result on nasal eosinophil count at Visit 1/1A.
  • Either subject's parent/guardian who signed ICF or subject is able to complete assessments on the patient diary through the study.
  • \< 2xULN; alkaline phosphatase and \<= 1.5xULN
  • Average of 3TNSS is >= 3.0 in the last consecutive 4 days prior to Visit 2.
  • Completion of the patient diary on >= 3 days of the last consecutive 4 days prior to Visit 2

Exclusion criteria

Exclusion Criteria:

  • Has a seasonal pollen as an allergen
  • A nose disorder that could affect the assessment of the study medication or eye or nose surgery (within 3 months prior to Visit 1)
  • Bacterial or viral infection of upper respiratory tract or eye
  • Concurrent disease/abnormalities: uncontrolled disease
  • Known to or any in the product
  • Has recent participation in a study and/or exposure to an investigational study drug within 3 months prior to Visit 1
  • Use of the following medication and/or its combination drug within the specified time:

Anti-IgE (Within 6 months prior to Visit 1), medications or Systemic corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to Visit 1

  • Affiliation with Investigator's Site: Relative or employee
  • History of alcohol or drug abuse, children in care or in the opinion of the investigator (sub-investigator), inappropriate to be enrolled in the study.
  • Bacterial or viral infection of upper respiratory tract or eye during the screening period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    GW685698X

    GW685698X 55mcg/day

    Drug: Fluticasone furoate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an other important medical event, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.

    Time frame: From the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks)

Secondary outcomes

  1. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophil Count at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline. Basophils, eosinophils, lymphocytes, monocytes, and total neutrophil counts are measured as the percentage of cells in white blood cells.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  2. Change From Baseline in Hemoglobin at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  3. Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  4. Change From Baseline in Red Blood Cell (RBC) Count at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  5. Change From Baseline in Hematocrit at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  6. Change From Baseline in Albumin and Total Protein at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  7. Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyltransferase (GGT) at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  8. Change From Baseline in Direct Bilirubin, Total Bilirubin, and Creatinine at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  9. Change From Baseline in Calcium, Chloride, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 4 and Week 12/Early Withdrawal

    Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

    Time frame: Baseline, Week 4, and Week 12/Early Withdrawal

  10. Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  11. Mean Percent Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  12. Mean Change From Baseline (BL) in Daily Variation of the 3 Total Nasal Symptom Score (3TNSS)

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The BL value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from BL was calculated as the mean score for the entire treatment period minus the score at BL. Only those participants available at the indicated time points were assessed.

    Time frame: Baseline, Day 1 to Day 84

  13. Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  14. Mean Percent Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  15. Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  16. Mean Percent Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  17. Mean Change From Baseline in Sneezing, Rhinorrhea, Nasal Congestion, and Nasal Itching Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  18. Mean Change From Baseline in Eye Itching, Tearing, and Redness Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    Three individual symptoms (eye itching, tearing, and redness) were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  19. Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

    The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

  20. Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge)

    Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).

    Time frame: Baseline, Week 4, Week 8, and Week 12/early withdrawal

  21. Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator

    The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

    Time frame: Week 12/early withdrawal

  22. Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant

    The participant's parent/guardian who signed the ICF or the participant himself/herself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

    Time frame: Week 12/early withdrawal

  23. Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=2 to <6 Years

    Pharmacokinetic (PK) samples were collected to analyze the plasma concentration of GW685698X.

    Time frame: Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)

  24. Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=6 to <15 Years

    PK samples were collected to analyze the plasma concentration of GW685698X.

    Time frame: Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)

07

Results

Posted Aug 12, 2013

Participant flow

Participant flow — Overall Study
MilestoneGW685698X 55 μg QD
Started61
Completed59
Not completed2
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an other important medical event, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.

Time frame:
From the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks)
Reported as:
Number · participants
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
participantsGW685698X 55 μg QD
Any AE41
Any SAE0
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophil Count at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline. Basophils, eosinophils, lymphocytes, monocytes, and total neutrophil counts are measured as the percentage of cells in white blood cells.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · Percentage of cells
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophil Count at Week 4 and Week 12/Early Withdrawal
Percentage of cellsGW685698X 55 μg QD
Basophils, Week 4, n=60-0.08 ± 0.353
Basophils, Week 12/early withdrawal, n=61-0.12 ± 0.356
Eosinophils, Week 4, n=60-0.29 ± 2.538
Eosinophils, Week 12/early withdrawal, n=61-1.38 ± 2.991
Lymphocytes, Week 4, n=60-1.22 ± 6.863
Lymphocytes, Week 12/early withdrawal, n=61-1.77 ± 8.181
Monocytes, Week 4, n=600.24 ± 1.604
Monocytes, Week 12/early withdrawal, n=610.26 ± 1.714
Total Neutrophils, Week 4, n=601.36 ± 8.355
Total Neutrophils, Week 12/early withdrawal, n=613.02 ± 9.684
SecondaryChange From Baseline in Hemoglobin at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · Grams per liter (grams/L)
Change From Baseline in Hemoglobin at Week 4 and Week 12/Early Withdrawal
Grams per liter (grams/L)GW685698X 55 μg QD
Hemoglobin, Week 4, n=60-1.9 ± 7.34
Hemoglobin, Week 12/early withdrawal, n=610.1 ± 6.09
SecondaryChange From Baseline in Platelet Count and White Blood Cell (WBC) Count at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · giga (10^9) cells (GI)/L
Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Week 4 and Week 12/Early Withdrawal
giga (10^9) cells (GI)/LGW685698X 55 μg QD
Platelet count, Week 4, n=60-0.4 ± 54.95
Platelet count, Week 12/early withdrawal, n=61-2.9 ± 56.26
WBC count, Week 4, n=60-0.45 ± 1.860
WBC count, Week 12/early withdrawal, n=61-0.00 ± 2.092
SecondaryChange From Baseline in Red Blood Cell (RBC) Count at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · tera (10^12) cells (TI)/L
Change From Baseline in Red Blood Cell (RBC) Count at Week 4 and Week 12/Early Withdrawal
tera (10^12) cells (TI)/LGW685698X 55 μg QD
RBC count, Week 4, n=60-0.081 ± 0.2386
RBC count, Week 12/early withdrawal, n=61-0.039 ± 0.2080
SecondaryChange From Baseline in Hematocrit at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · Proportion of RBCs in blood
Change From Baseline in Hematocrit at Week 4 and Week 12/Early Withdrawal
Proportion of RBCs in bloodGW685698X 55 μg QD
Hematocrit, Week 4, n=60-0.0061 ± 0.01965
Hematocrit, Week 12/early withdrawal, n=61-0.0062 ± 0.01824
SecondaryChange From Baseline in Albumin and Total Protein at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · grams/L
Change From Baseline in Albumin and Total Protein at Week 4 and Week 12/Early Withdrawal
grams/LGW685698X 55 μg QD
Albumin, Week 4, n=60-1.4 ± 2.05
Albumin, Week 12/early withdrawal, n=61-0.8 ± 1.93
Total protein, Week 4, n=60-1.8 ± 3.41
Total protein, Week 12/early withdrawal, n=61-0.9 ± 3.36
SecondaryChange From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyltransferase (GGT) at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · International units (IU)/L
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyltransferase (GGT) at Week 4 and Week 12/Early Withdrawal
International units (IU)/LGW685698X 55 μg QD
ALP, Week 4, n=60-49.9 ± 89.43
ALP, Week 12/early withdrawal, n=6188.5 ± 586.10
ALT, Week 4, n=600.7 ± 4.19
ALT, Week 12/early withdrawal, n=610.4 ± 4.72
AST, Week 4, n=60-0.3 ± 3.45
AST, Week 12/early withdrawal, n=610.2 ± 3.39
GGT, Week 4, n=60-0.1 ± 1.63
GGT, Week 12/early withdrawal, n=610.1 ± 1.95
SecondaryChange From Baseline in Direct Bilirubin, Total Bilirubin, and Creatinine at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · Micromoles (μmol)/L
Change From Baseline in Direct Bilirubin, Total Bilirubin, and Creatinine at Week 4 and Week 12/Early Withdrawal
Micromoles (μmol)/LGW685698X 55 μg QD
Direct bilirubin, Week 4, n=600.114 ± 0.9889
Direct bilirubin, Week 12/early withdrawal, n=61-0.028 ± 0.8545
Total bilirubin, Week 4, n=600.370 ± 2.2504
Total bilirubin, Week 12/early withdrawal, n=61-0.533 ± 2.2844
Creatinine, Week 4, n=60-1.6649 ± 5.21356
Creatinine, Week 12/early withdrawal, n=61-0.5797 ± 5.63473
SecondaryChange From Baseline in Calcium, Chloride, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 4 and Week 12/Early Withdrawal

Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.

Time frame:
Baseline, Week 4, and Week 12/Early Withdrawal
Reported as:
Mean · Millimoles (mmol)/L
Change From Baseline in Calcium, Chloride, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 4 and Week 12/Early Withdrawal
Millimoles (mmol)/LGW685698X 55 μg QD
Calcium, Week 4, n=60-0.0541 ± 0.09085
Calcium, Week 12/early withdrawal, n=61-0.0372 ± 0.07480
Chloride, Week 4, n=601.3 ± 2.27
Chloride, Week 12/early withdrawal, n=611.1 ± 2.04
Potassium, Week 4, n=60-0.13 ± 0.378
Potassium, Week 12/early withdrawal, n=61-0.06 ± 0.380
Sodium, Week 4, n=60-0.4 ± 1.70
Sodium, Week 12/early withdrawal, n=61-1.2 ± 1.58
Urea/BUN, Week 4, n=60-0.4998 ± 1.12504
Urea/BUN, Week 12/early withdrawal, n=61-0.0954 ± 1.18765
SecondaryMean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Entire Treatment Period, n=61-2.2 ± 1.65
Week 1 to 2, n=61-1.6 ± 1.58
Week 3 to 4, n=61-2.5 ± 1.84
Week 7 to 8, n=60-2.4 ± 1.86
Week 11 to 12, n=60-2.0 ± 2.07
SecondaryMean Percent Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Percent changeGW685698X 55 μg QD
Entire Treatment Period, n=61-46.9 ± 33.25
Week 1 to 2, n=61-31.6 ± 36.36
Week 3 to 4, n=61-53.2 ± 36.81
Week 7 to 8, n=60-50.9 ± 38.00
Week 11 to 12, n=60-40.7 ± 41.58
SecondaryMean Change From Baseline (BL) in Daily Variation of the 3 Total Nasal Symptom Score (3TNSS)

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The BL value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from BL was calculated as the mean score for the entire treatment period minus the score at BL. Only those participants available at the indicated time points were assessed.

Time frame:
Baseline, Day 1 to Day 84
Reported as:
Mean · Scores on a scale
Mean Change From Baseline (BL) in Daily Variation of the 3 Total Nasal Symptom Score (3TNSS)
Scores on a scaleGW685698X 55 μg QD
Day 1, n=61-0.5 ± 1.81
Day 2, n=61-0.8 ± 1.90
Day 3, n=61-0.9 ± 1.64
Day 4, n=61-1.3 ± 1.76
Day 5, n=61-1.4 ± 1.75
Day 6, n=61-1.3 ± 1.76
Day 7, n=61-1.6 ± 1.83
Day 8, n=61-1.9 ± 1.94
Day 9, n=61-1.9 ± 2.12
Day 10, n=61-2.0 ± 1.90
Day 11, n=61-1.8 ± 2.18
Day 12, n=61-1.9 ± 1.98
Day 13, n=61-2.3 ± 2.12
Day 14, n=61-2.2 ± 2.21
Day 15, n=61-2.5 ± 2.12
Day 16, n=61-2.3 ± 2.05
Day 17, n=61-2.4 ± 2.01
Day 18, n=61-2.5 ± 1.96
Day 19, n=61-2.6 ± 2.01
Day 20, n=61-2.7 ± 2.00
Day 21, n=61-2.5 ± 2.08
Day 22, n=61-2.6 ± 2.03
Day 23, n=61-2.4 ± 2.04
Day 24, n=61-2.4 ± 2.13
Day 25, n=61-2.5 ± 1.91
Day 26, n=61-2.5 ± 2.08
Day 27, n=61-2.5 ± 1.97
Day 28, n=61-2.4 ± 1.99
Day 29, n=60-2.4 ± 1.81
Day 30, n=60-2.5 ± 1.79
Day 31, n=60-2.6 ± 1.90
Day 32, n=60-2.4 ± 2.16
Day 33, n=60-2.5 ± 1.99
Day 34, n=60-2.4 ± 2.30
Day 35, n=60-2.4 ± 2.43
Day 36, n=60-2.2 ± 2.21
Day 37, n=60-2.4 ± 2.23
Day 38, n=60-2.4 ± 2.41
Day 39, n=60-2.2 ± 2.30
Day 40, n=60-2.2 ± 2.17
Day 41, n=60-2.3 ± 1.85
Day 42, n=60-2.6 ± 1.80
Day 43, n=60-2.4 ± 2.20
Day 44, n=60-2.5 ± 2.16
Day 45, n=60-2.2 ± 2.24
Day 46, n=60-2.5 ± 1.89
Day 47, n=60-2.5 ± 2.07
Day 48, n=60-2.4 ± 2.27
Day 49, n=60-2.4 ± 2.15
Day 50, n=60-2.4 ± 2.33
Day 51, n=60-2.4 ± 2.34
Day 52, n=60-2.4 ± 1.99
Day 53, n=60-2.5 ± 1.90
Day 54, n=60-2.2 ± 1.98
Day 55, n=60-2.2 ± 2.11
Day 56, n=60-2.3 ± 2.11
Day 57, n=60-2.4 ± 1.94
Day 58, n=60-2.4 ± 1.98
Day 59, n=60-2.6 ± 2.09
Day 60, n=60-2.8 ± 1.75
Day 61, n=60-2.5 ± 1.78
Day 62, n=60-2.6 ± 1.65
Day 63, n=60-2.7 ± 1.77
Day 64, n=60-2.6 ± 1.96
Day 65, n=60-2.5 ± 2.07
Day 66, n=60-2.2 ± 2.24
Day 67, n=60-2.4 ± 2.10
Day 68, n=60-2.3 ± 2.23
Day 69, n=60-2.4 ± 1.96
Day 70, n=60-2.5 ± 1.79
Day 71, n=60-2.4 ± 1.99
Day 72, n=60-2.1 ± 1.97
Day 73, n=60-2.0 ± 2.17
Day 74, n=59-1.6 ± 2.37
Day 75, n=59-1.8 ± 2.34
Day 76, n=59-1.8 ± 2.56
Day 77, n=59-2.1 ± 2.59
Day 78, n=59-2.1 ± 2.49
Day 79, n=59-1.9 ± 2.35
Day 80, n=59-1.8 ± 2.15
Day 81, n=50-1.9 ± 2.25
Day 82, n=43-1.7 ± 2.45
Day 83, n=39-1.2 ± 2.55
Day 84, n=31-1.2 ± 2.55
SecondaryMean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Scores on a scale-2.6 ± 2.01
Week 1 to 2 n=61-1.8 ± 1.93
Week 3 to 4, n=61-2.9 ± 2.26
Week 7 to 8, n=60-2.8 ± 2.26
Week 11 to 12, n=60-2.3 ± 2.50
SecondaryMean Percent Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Percent changeGW685698X 55 μg QD
Entire Treatment Period, n=61-47.1 ± 34.06
Week 1 to 2, n=61-31.3 ± 38.42
Week 3 to 4, n=61-52.8 ± 38.62
Week 7 to 8, n=60-51.3 ± 38.90
Week 11 to 12, n=60-42.0 ± 41.95
SecondaryMean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Entire Treatment Period, n=61-0.2 ± 1.00
Week 1 to 2, n=61-0.1 ± 0.88
Week 3 to 4, n=61-0.1 ± 1.08
Week 7 to 8, n=60-0.2 ± 1.20
Week 11 to 12, n=60-0.3 ± 1.06
SecondaryMean Percent Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Percent changeGW685698X 55 μg QD
Entire Treatment Period, n=367.1 ± 180.60
Week 1 to 2, n=364.6 ± 138.41
Week 3 to 4, n=3617.5 ± 214.79
Week 7 to 8, n=3529.0 ± 251.46
Week 11 to 12, n=35-22.5 ± 163.35
SecondaryMean Change From Baseline in Sneezing, Rhinorrhea, Nasal Congestion, and Nasal Itching Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Sneezing, Rhinorrhea, Nasal Congestion, and Nasal Itching Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Sneezing, Entire Treatment Period, n=61-0.7 ± 0.74
Sneezing, Week 1 to 2, n=61-0.5 ± 0.67
Sneezing, Week 3 to 4, n=61-0.8 ± 0.75
Sneezing, Week 7 to 8, n=60-0.7 ± 0.81
Sneezing, Week 11 to 12, n=60-0.6 ± 0.88
Rhinorrhea, Entire Treatment Period, n=61-0.8 ± 0.65
Rhinorrhea, Week 1 to 2, n=61-0.5 ± 0.62
Rhinorrhea, Week 3 to 4, n=61-0.9 ± 0.76
Rhinorrhea, Week 7 to 8, n=60-0.8 ± 0.73
Rhinorrhea, Week 11 to 12, n=60-0.7 ± 0.85
Nasal Congestion, Entire Treatment Period, n=61-0.8 ± 0.66
Nasal Congestion, Week 1 to 2, n=61-0.5 ± 0.63
Nasal Congestion, Week 3 to 4, n=61-0.9 ± 0.76
Nasal Congestion, Week 7 to 8, n=60-0.8 ± 0.72
Nasal Congestion, Week 11 to 12, n=60-0.7 ± 0.85
Nasal Itching, Entire Treatment Period, n=61-0.4 ± 0.58
Nasal Itching, Week 1 to 2, n=61-0.2 ± 0.55
Nasal Itching, Week 3 to 4, n=61-0.4 ± 0.63
Nasal Itching, Week 7 to 8, n=60-0.4 ± 0.67
Nasal Itching, Week 11 to 12, n=60-0.3 ± 0.69
SecondaryMean Change From Baseline in Eye Itching, Tearing, and Redness Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

Three individual symptoms (eye itching, tearing, and redness) were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Eye Itching, Tearing, and Redness Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Eye Itching, Entire Treatment Period, n=61-0.2 ± 0.57
Eye Itching, Week 1 to 2, n=61-0.1 ± 0.53
Eye Itching, Week 3 to 4, n=61-0.1 ± 0.61
Eye Itching, Week 7 to 8, n=60-0.2 ± 0.68
Eye Itching, Week 11 to 12, n=60-0.2 ± 0.59
Tearing, Entire Treatment Period, n=610.0 ± 0.25
Tearing, Week 1 to 2, n=610.0 ± 0.22
Tearing, Week 3 to 4, n=610.0 ± 0.29
Tearing, Week 7 to 8, n=600.0 ± 0.28
Tearing, Week 11 to 12, n=600.0 ± 0.26
Redness, Entire Treatment Period, n=61-0.1 ± 0.34
Redness, Week 1 to 2, n=61-0.0 ± 0.32
Redness, Week 3 to 4, n=61-0.0 ± 0.35
Redness, Week 7 to 8, n=60-0.0 ± 0.43
Redness, Week 11 to 12, n=60-0.1 ± 0.39
SecondaryMean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12

The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Scores on a scaleGW685698X 55 μg QD
Entire Treatment Period, n=61-0.5 ± 0.61
Week 1 to 2, n=61-0.3 ± 0.52
Week 3 to 4, n=61-0.5 ± 0.65
Week 7 to 8, n=60-0.6 ± 0.72
Week 11 to 12, n=60-0.4 ± 0.75
SecondaryNumber of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge)

Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).

Time frame:
Baseline, Week 4, Week 8, and Week 12/early withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge)
participantsGW685698X 55 μg QD
SOITM, Baseline, Score 0, n=613
SOITM, Baseline, Score 1, n=619
SOITM, Baseline, Score 2, n=6135
SOITM, Baseline, Score 3, n=6114
SOITM, Week 4, Score 0, n=6015
SOITM, Week 4, Score 1, n=6021
SOITM, Week 4, Score 2, n=6023
SOITM, Week 4, Score 3, n=601
SOITM, Week 8, Score 0, n=6017
SOITM, Week 8, Score 1, n=6024
SOITM, Week 8, Score 2, n=6019
SOITM, Week 8, Score 3, n=600
SOITM, Week 12/early withdrawal, Score 0, n=6121
SOITM, Week 12/early withdrawal, Score 1, n=6126
SOITM, Week 12/early withdrawal, Score 2, n=6113
SOITM, Week 12/early withdrawal, Score 3, n=611
COITM, Baseline, Score 0, n=610
COITM, Baseline, Score 1, n=6110
COITM, Baseline, Score 2, n=6123
COITM, Baseline, Score 3, n=6128
COITM, Week 4, Score 0, n=6010
COITM, Week 4, Score 1, n=6028
COITM, Week 4, Score 2, n=6013
COITM, Week 4, Score 3, n=609
COITM, Week 8, Score 0, n=6012
COITM, Week 8, Score 1, n=6030
COITM, Week 8, Score 2, n=6011
COITM, Week 8, Score 3, n=607
COITM, Week 12/early withdrawal, Score 0, n=6119
COITM, Week 12/early withdrawal, Score 1, n=6128
COITM, Week 12/early withdrawal, Score 2, n=6110
COITM, Week 12/early withdrawal, Score 3, n=614
QTND, Baseline, Score 0, n=614
QTND, Baseline, Score 1, n=6116
QTND, Baseline, Score 2, n=6133
QTND, Baseline, Score 3, n=618
QTND, Week 4, Score 0, n=6030
QTND, Week 4, Score 1, n=6024
QTND, Week 4, Score 2, n=605
QTND, Week 4, Score 3, n=601
QTND, Week 8, Score 0, n=6029
QTND, Week 8, Score 1, n=6025
QTND, Week 8, Score 2, n=604
QTND, Week 8, Score 3, n=602
QTND, Week 12/early withdrawal, Score 0, n=6134
QTND, Week 12/early withdrawal, Score 1, n=6124
QTND, Week 12/early withdrawal, Score 2, n=613
QTND, Week 12/early withdrawal, Score 3, n=610
QLND, Baseline, Score 0, n=614
QLND, Baseline, Score 1, n=610
QLND, Baseline, Score 2, n=6114
QLND, Baseline, Score 3, n=6143
QLND, Week 4, Score 0, n=6030
QLND, Week 4, Score 1, n=6011
QLND, Week 4, Score 2, n=604
QLND, Week 4, Score 3, n=6015
QLND, Week 8, Score 0, n=6030
QLND, Week 8, Score 1, n=6013
QLND, Week 8, Score 2, n=605
QLND, Week 8, Score 3, n=6012
QLND, Week 12/early withdrawal, Score 0, n=6132
QLND, Week 12/early withdrawal, Score 1, n=6110
QLND, Week 12/early withdrawal, Score 2, n=617
QLND, Week 12/early withdrawal, Score 3, n=6112
SecondaryNumber of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator

The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

Time frame:
Week 12/early withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
participantsGW685698X 55 μg QD
Significantly Improved25
Moderately Improved28
Mildly Improved3
No Change5
Mildly Worse0
Moderately Worse0
Significantly Worse0
SecondaryNumber of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant

The participant's parent/guardian who signed the ICF or the participant himself/herself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

Time frame:
Week 12/early withdrawal
Reported as:
Number · participants
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
participantsGW685698X 55 μg QD
Significantly Improved13
Moderately Improved31
Mildly Improved12
No Change4
Mildly Worse1
Moderately Worse0
Significantly Worse0
SecondaryNumber of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=2 to <6 Years

Pharmacokinetic (PK) samples were collected to analyze the plasma concentration of GW685698X.

Time frame:
Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)
Reported as:
Number · participants
Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=2 to <6 Years
participantsGW685698X 55 μg QD
Not Quantifiable (<10 picograms/milliliter [pg/mL]17
>=10 to <20 pg/mL2
>=20 to <30 pg/mL0
>=30 pg/mL0
SecondaryNumber of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=6 to <15 Years

PK samples were collected to analyze the plasma concentration of GW685698X.

Time frame:
Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)
Reported as:
Number · participants
Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=6 to <15 Years
participantsGW685698X 55 μg QD
Not Quantifiable (<10 pg/mL)37
>=10 to <20 pg/mL2
>=20 to <30 pg/mL1
>=30 pg/mL0

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GW685698X 55 μg QD—0/61 (0%)23/61 (37.7%)
Most frequent other events
Most frequent other events
EventGW685698X 55 μg QD
NasopharyngitisInfections and infestations15/61
Acute sinusitisInfections and infestations8/61

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GW685698X 55 μg QD
Mean8.0 ± 3.59
Gender
Gender(Participants)GW685698X 55 μg QD
Female19
Male42
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)GW685698X 55 μg QD
Asian - Japanese Heritage61
08

Study locations

6 sites
  • GSK Investigational Site
    Chiba, 272-0143, Japan
  • GSK Investigational Site
    Chiba, 277-0882, Japan
  • GSK Investigational Site
    Gifu, 501-3247, Japan
  • GSK Investigational Site
    Saitama, 355-0062, Japan
  • GSK Investigational Site
    Tokyo, 160-0017, Japan
  • GSK Investigational Site
    Tokyo, 170-0005, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2012
First posted
Jun 19, 2012
Start
Jun 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Aug 12, 2013
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01622231
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 19, 2012
Start date
Jun 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Aug 12, 2013
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion